Anti-CTA monoclonal antibodies - Xenova Group

Drug Profile

Anti-CTA monoclonal antibodies - Xenova Group

Alternative Names: HumaRADHN; HumaRADOV; KSB 309; KSB 310

Latest Information Update: 04 Aug 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Intracel Corporation
  • Developer Intracel Corporation; University of Nebraska Medical Center; Xenova Group
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Head and neck cancer; Ovarian cancer

Most Recent Events

  • 04 Aug 2004 Discontinued - Phase-I for Head and neck cancer in USA (unspecified route)
  • 04 Aug 2004 Discontinued - Phase-I for Ovarian cancer in USA (unspecified route)
  • 25 Sep 2003 KS Biomedix Holdings has been acquired by Xenova Group
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top